Addex Therapeutics Ltd (SWX: ADXN)
Switzerland
· Delayed Price · Currency is CHF 0.0672
-0.0004 (-0.59%)
Oct 1, 2024, 5:30 PM CET
Addex Therapeutics Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 0.83 | 1.61 | 1.42 | 2.92 | 3.61 | 2.76 | Upgrade
|
| Other Revenue | 0.03 | 0.03 | 0.02 | 0.24 | 0.27 | 0.07 | Upgrade
|
| Revenue | 0.86 | 1.65 | 1.44 | 3.15 | 3.88 | 2.83 | Upgrade
|
| Revenue Growth (YoY) | -59.82% | 13.99% | -54.18% | -18.71% | 36.89% | -57.72% | Upgrade
|
| Cost of Revenue | 6.97 | 6.94 | 14.62 | 12.82 | 10.37 | 12.43 | Upgrade
|
| Gross Profit | -6.11 | -5.29 | -13.18 | -9.67 | -6.49 | -9.59 | Upgrade
|
| Selling, General & Admin | 5.1 | 4.99 | 7.34 | 5.84 | 5.75 | 5.01 | Upgrade
|
| Operating Expenses | 5.1 | 4.99 | 7.34 | 5.84 | 5.75 | 5.01 | Upgrade
|
| Operating Income | -11.2 | -10.28 | -20.52 | -15.51 | -12.24 | -14.6 | Upgrade
|
| Interest Expense | -0.02 | -0.02 | -0.05 | -0.06 | -0.07 | -0.13 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.06 | 0.03 | 0.01 | 0.04 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.14 | -0.32 | -0.26 | 0.21 | -0.58 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -11.86 | -10.56 | -20.8 | -15.35 | -12.86 | -14.78 | Upgrade
|
| Pretax Income | -11.86 | -10.56 | -20.8 | -15.35 | -12.86 | -14.78 | Upgrade
|
| Net Income | 4.32 | -10.56 | -20.8 | -15.35 | -12.86 | -14.78 | Upgrade
|
| Net Income to Common | 4.32 | -10.56 | -20.8 | -15.35 | -12.86 | -14.78 | Upgrade
|
| Shares Outstanding (Basic) | 90 | 74 | 45 | 34 | 27 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 74 | 45 | 34 | 27 | 26 | Upgrade
|
| Shares Change (YoY) | 50.83% | 64.45% | 32.43% | 27.88% | 0.96% | 13.46% | Upgrade
|
| EPS (Basic) | 0.05 | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | Upgrade
|
| EPS (Diluted) | 0.05 | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | Upgrade
|
| Free Cash Flow | -7.83 | -8 | -16.44 | -14.74 | -12.24 | -9.51 | Upgrade
|
| Free Cash Flow Per Share | -0.09 | -0.11 | -0.36 | -0.43 | -0.46 | -0.36 | Upgrade
|
| Gross Margin | - | - | - | - | -167.41% | - | Upgrade
|
| Operating Margin | -1298.01% | -624.22% | -1420.12% | -491.74% | -315.62% | -515.38% | Upgrade
|
| Profit Margin | 500.17% | -640.91% | -1439.78% | -486.85% | -331.48% | -521.61% | Upgrade
|
| Free Cash Flow Margin | -906.88% | -485.67% | -1137.59% | -467.34% | -315.52% | -335.63% | Upgrade
|
| EBITDA | -11.07 | -10.26 | -20.23 | -15.16 | -11.86 | -14.59 | Upgrade
|
| D&A For EBITDA | 0.13 | 0.03 | 0.29 | 0.35 | 0.38 | 0.01 | Upgrade
|
| EBIT | -11.2 | -10.28 | -20.52 | -15.51 | -12.24 | -14.6 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.